Pharma, Biotech and Life Science Reports Financial Indicators with Substantial Growth
Pharma, Biotech and Life Science, a leading player in the Saudi Exchange's Main Market, has released its financial indicators for August 10, 2025. The company, which operates in the vital healthcare sector, has achieved substantial growth, with a net income of SAR 3,393.53 million and shareholders' equity of SAR 16.94 billion. This indicates the company's capital base and financial stability, with a market capitalization valued at SAR 16.94 billion, accounting for a notable 0.19% of the market. The company's earnings per share (EPS) of SAR 2.703 and price-to-earnings (P/E) ratio of 29.847 demonstrate its profitable operations and investor sentiment towards its growth prospects.
Key Takeaways:
- The company's net income for the period is SAR 3,393.53 million, reflecting its profitable operations.
- Shareholders' equity stands at SAR 16.94 billion, indicating substantial capital base and financial stability.
- Market capitalization is valued at SAR 16.94 billion, accounting for 0.19% of the market.
- Earnings per share (EPS) stands at SAR 2.703, with a price-to-earnings (P/E) ratio of 29.847.
- The company has issued shares amounting to 567.57 million.
- Pharma, Biotech and Life Science operates in the healthcare sector, a vital industry for the Saudi economy.
- The company's financial indicators reflect its ongoing commitment to sustaining its market position and shareholder value.
Statistics:
- Market capitalization: SAR 16.94 billion
- Percentage market cap: 0.19%
- Net income: SAR 3,393.53 million
- Shareholders' equity: SAR 16.94 billion
- Earnings per share (EPS): SAR 2.703
- Price-to-earnings (P/E) ratio: 29.847
- Number of issued shares: 567.57 million
- Book value: SAR 16.16
- Price-to-book value (P/B V) ratio: 4.99
Sources:
- Saudi Exchange